TY - JOUR
T1 - MYORG-related disease is associated with central pontine calcifications and atypical parkinsonism
AU - Chelban, Viorica
AU - Carecchio, Miryam
AU - Rea, Gillian
AU - Bowirrat, Abdalla
AU - Kirmani, Salman
AU - Magistrelli, Luca
AU - Efthymiou, Stephanie
AU - Schottlaender, Lucia
AU - Vandrovcova, Jana
AU - Salpietro, Vincenzo
AU - Salsano, Ettore
AU - Pareyson, Davide
AU - Chiapparini, Luisa
AU - Jan, Farida
AU - Ibrahim, Shahnaz
AU - Khan, Fatima
AU - Qarnain, Zul
AU - Groppa, Stanislav
AU - Bajaj, Nin
AU - Balint, Bettina
AU - Bhatia, Kailash P.
AU - Lees, Andrew
AU - Morrison, Patrick J.
AU - Wood, Nicholas W.
AU - Garavaglia, Barbara
AU - Houlden, Henry
N1 - Publisher Copyright:
© American Academy of Neurology.
PY - 2020
Y1 - 2020
N2 - ObjectiveTo identify the phenotypic, neuroimaging, and genotype-phenotype expression of MYORG mutations.MethodsUsing next-generation sequencing, we screened 86 patients with primary familial brain calcification (PFBC) from 60 families with autosomal recessive or absent family history that were negative for mutations in SLC20A2, PDGFRB, PDGBB, and XPR1. In-depth phenotyping and neuroimaging investigations were performed in all cases reported here.ResultsWe identified 12 distinct deleterious MYORG variants in 7 of the 60 families with PFBC. Overall, biallelic MYORG mutations accounted for 11.6% of PFBC families in our cohort. A heterogeneous phenotypic expression was identified within and between families with a median age at onset of 56.4 years, a variable combination of parkinsonism, cerebellar signs, and cognitive decline. Psychiatric disturbances were not a prominent feature. Cognitive assessment showed impaired cognitive function in 62.5% of cases. Parkinsonism associated with vertical nuclear gaze palsy was the initial clinical presentation in 1/3 of cases and was associated with central pontine calcifications. Cerebral cortical atrophy was present in 37% of cases.ConclusionsThis large, multicentric study shows that biallelic MYORG mutations represent a significant proportion of autosomal recessive PFBC. We recommend screening MYORG mutations in all patients with primary brain calcifications and autosomal recessive or negative family history, especially when presenting clinically as atypical parkinsonism and with pontine calcification on brain CT.
AB - ObjectiveTo identify the phenotypic, neuroimaging, and genotype-phenotype expression of MYORG mutations.MethodsUsing next-generation sequencing, we screened 86 patients with primary familial brain calcification (PFBC) from 60 families with autosomal recessive or absent family history that were negative for mutations in SLC20A2, PDGFRB, PDGBB, and XPR1. In-depth phenotyping and neuroimaging investigations were performed in all cases reported here.ResultsWe identified 12 distinct deleterious MYORG variants in 7 of the 60 families with PFBC. Overall, biallelic MYORG mutations accounted for 11.6% of PFBC families in our cohort. A heterogeneous phenotypic expression was identified within and between families with a median age at onset of 56.4 years, a variable combination of parkinsonism, cerebellar signs, and cognitive decline. Psychiatric disturbances were not a prominent feature. Cognitive assessment showed impaired cognitive function in 62.5% of cases. Parkinsonism associated with vertical nuclear gaze palsy was the initial clinical presentation in 1/3 of cases and was associated with central pontine calcifications. Cerebral cortical atrophy was present in 37% of cases.ConclusionsThis large, multicentric study shows that biallelic MYORG mutations represent a significant proportion of autosomal recessive PFBC. We recommend screening MYORG mutations in all patients with primary brain calcifications and autosomal recessive or negative family history, especially when presenting clinically as atypical parkinsonism and with pontine calcification on brain CT.
UR - http://www.scopus.com/inward/record.url?scp=85085357367&partnerID=8YFLogxK
U2 - 10.1212/NXG.0000000000000399
DO - 10.1212/NXG.0000000000000399
M3 - Article
AN - SCOPUS:85085357367
SN - 2376-7839
VL - 6
JO - Neurology: Genetics
JF - Neurology: Genetics
IS - 2
M1 - e399
ER -